Article type: Commentary Article

Home Page URL: https://www.alliedacademies.org/molecular-oncology-research/volume-selector.php

Unlocking the future of cancer therapy: The role of micrornas in molecular oncology research.

Suresh Kumar*

Department of Molecular Genetics, MKSG University, India

***Correspondence to:** Suresh Kumar, Department of Molecular Genetics, MKSG University, India, E mail: suresh.kumar@icpo.icmr.in

Received: *01-Aug-2025, Manuscript No. AAMOR-25-166744;* ***Editor assigned:*** *02-Aug-2025, PreQC No. AAMOR-25-166744(PQ);* ***Reviewed:*** *16-Aug-2025, QC No. AAMOR-25-166744;* ***Revised:*** *21-Aug-2025, Manuscript No. AAMOR-25-166744(R);* ***Published:*** *28-Aug-2025, DOI:10.35841/aamor-9.3.291*

Introduction

Cancer continues to be a major global health burden, demanding advanced and precise therapeutic strategies. Among the emerging frontiers in molecular oncology research, microRNAs (miRNAs) have attracted significant attention due to their unique ability to regulate gene expression post-transcriptionally. To overcome these obstacles, integrative molecular oncology research is focusing on combining miRNA profiling with other omics data (genomics, proteomics, epigenomics) to develop comprehensive, personalized cancer treatment strategies. The application of artificial intelligence (AI) and machine learning is also being utilized to decode complex miRNA regulatory networks, enhancing target prediction and therapeutic design. These small, non-coding RNA molecules play pivotal roles in various biological processes, including cell growth, apoptosis, and differentiation—all of which are critical in the development and progression of cancer [1].

For instance, miR-21, one of the most studied oncogenic miRNAs, is overexpressed in multiple cancer types such as breast, lung, and colorectal cancers. It promotes tumor growth by inhibiting tumor suppressor genes like PTEN and PDCD4. On the other hand, miR-34a, a tumor-suppressive miRNA, targets genes involved in cell cycle progression and evasion of apoptosis. Its downregulation in cancers like pancreatic and prostate malignancies is associated with poor prognosis. Recent studies in oncology have revealed that miRNAs function both as oncogenes and tumor suppressors, depending on the cellular context and target genes involved. As such, miRNAs represent a promising class of molecular biomarkers and therapeutic agents that could revolutionize cancer diagnosis and treatment [2, 3].

Tiny Regulators with Massive Impact MiRNAs are short RNA sequences, typically 18–24 nucleotides in length, that silence gene expression by binding to complementary sequences on target messenger RNAs (mRNAs). This interaction either inhibits translation or leads to mRNA degradation. In the context of cancer, deregulation of miRNA expression has been linked to tumorigenesis, metastasis, and resistance to therapy. MiRNAs as Biomarkers in Cancer Diagnosis and Prognosis One of the most promising applications of miRNAs in oncology is their use as non-invasive biomarkers. MiRNAs are remarkably stable in biological fluids, such as blood, urine, and saliva, making them ideal candidates for liquid biopsies. Their expression profiles can serve as diagnostic signatures for early cancer detection and prognostic indicators of disease outcome [4, 5].

For example, altered levels of circulating miRNAs have been successfully used to differentiate between benign and malignant tumors, monitor therapeutic response, and predict relapse. This non-invasive approach could minimize the need for traditional, invasive biopsy procedures and enable real-time monitoring of cancer progression. Therapeutic Potential of miRNA Modulation MiRNA-based therapeutics are being actively explored to restore

normal gene expression in cancer cells. Two major strategies are currently being investigated: miRNA mimics (to restore downregulated tumor-suppressor miRNAs) and antagomiRs (to inhibit overexpressed oncogenic miRNAs) [6, 7].

Preclinical studies have shown promising results. For instance, miR-34 mimics have demonstrated tumor-suppressive effects in lung and liver cancer models. Meanwhile, antagomiRs against miR-155, an oncogenic miRNA, have shown potential in treating lymphoma. The therapeutic delivery of these agents is being enhanced by nanoparticle-based systems, which improve their stability and target specificity. While miRNA therapeutics are still in early phases of clinical development, their potential to modulate entire gene networks offers a powerful tool in cancer therapy, especially when combined with existing treatments such as chemotherapy, immunotherapy, and radiation [8, 9].

Challenges and Future Perspectives Despite the immense promise, there are several challenges in translating miRNA research into clinical practice. The off-target effects, delivery mechanisms, and immune responses triggered by synthetic miRNAs must be carefully addressed. Additionally, the heterogeneity of tumors and patient-specific variations in miRNA expression complicate universal treatment approaches [10].

Conclusion

MicroRNAs are emerging as game-changers in the field of molecular oncology, offering new avenues for early detection, prognosis, and personalized cancer therapy. As our understanding of miRNA biology deepens and technological innovations address current limitations, miRNA-based applications are poised to enter mainstream clinical practice. Continued collaboration among researchers, clinicians, and regulatory bodies will be crucial to harness the full potential of microRNAs and transform the future of cancer care.

References

1. Pirami L, Giache V, Becciolini A, et al. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J Clin Path. 1997;50:600-4.
2. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991;65:606-12.
3. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
4. Hwang ES, Nottoli T, Dimaio D, et al. The HPV16 E5 Protein: Expression, Detection, and Stable Complex Formation with Transmembrane Proteins in COS Cells. Virol. 1995;211:227-233.
5. Oh JM, Kim SH, Cho EA, et al. Juhnn. Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinog. 2010;31:402-10.
6. Schmandt RE, Iglesias DA, Co NN,et al.Understanding obesity and endometrial cancer risk: opportunities for prevention. Ameri Jour of Obs and Gyneco. 2011;205(6):518-25.
7. Kurman RJ, Kaminski PF, Norris HJ.The behavior of endometrial hyperplasia. A long?term study of “untreated” hyperplasia in 170 patients. Canc. 1985;56(2):403-12.
8. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Canc. 2006;106(4):812-9.
9. Shutter J, Wright Jr TC. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Inter Jour of Gyneco Patho. 2005;24(4):313-8.
10. Hahn HS, Chun YK, Kwon YI, et al. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. Euro Jour of Obst & Gyneco and Repro Bio. 2010;150(1):80-3.

Citation: Kumar S. Unlocking the future of cancer therapy: The role of micrornas in molecular oncology research. J Mol Oncol Res. 2025;9(3):291